Trial Profile

Phase I study of Ramucirumab and Irinotecan for metastatic gastric cancer previously treated with Fluoropyrimidine with/without Platinum and Taxane

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 15 Feb 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Irinotecan (Primary) ; Ramucirumab (Primary)
Indications Adenocarcinoma; Gastric cancer
Focus Adverse reactions
Acronyms G-IRIRAM

Most Recent Events

09 Feb 2019 Status changed from active, no longer recruiting to completed.
20 Jan 2018 Results (n=6) assessing maximum tolerated dose and recommended dose of ramucirumab plus irinotecan, presented at the 2018 Gastrointestinal Cancers Symposium.
17 Jun 2017 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com